| N (cases) | 103 |
| IBS | 26 |
| CD | 40 |
| UC | 37 |
| Age(years) |
|
| IBS | 45.00 ± 16.00 |
| IBD | 34.74 ± 15.61 |
| CD | 25.30 ± 10.08 |
| UC | 44.94 ± 14.09 |
| Male gender(cases) |
|
| IBS | 12 (46.15%) |
| IBD | 48 (62.34%) |
| CD | 26 (65.00%) |
| UC | 22 (59.46%) |
| FC by ELISA(μg/g) |
|
| IBS | 41.44 (11.77 ~ 73.19) |
| IBD in clinical remission stage | 338.46 (53.08 - 692.82) |
| IBD in clinical active stage | 716.99 (240.42 ~ 1232.53) |
| FC by FEIA(μg/g) |
|
| IBS | 39.04 (12.09 ~ 81.04) |
| IBD in clinical remission stage | 407.36 (121.81 ~ 878.48) |
| IBD in clinical active stage | 699.91 (346.14 ~ 1647.54)* |